Oxford Genome Sciences, Amgen To Collaborate on Cancer Antibodies | GenomeWeb
NEW YORK (GenomeWeb News) - Oxford Genome Sciences said last weekthat it is collaborating with Amgen to discover, develop, and commercialize therapeutic antibodies for cancer.
 
The companies will use Amgen’s XenoMouse technology to generate fully human anibodies, which will be raised against druggable targets that Oxford Genome Sciences has identified through its Oxford Genome Anatomy Project database of cancer proteins.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.